4932438H23Rik Inhibitors
Epcip Inhibitors as a chemical class refers to compounds that can indirectly modulate the function or interactions of exosomal polycystin 1 interacting protein (EPCIP) by targeting processes related to exosome formation, release, or exosomal content management. Since EPCIP is associated with exosomes, inhibitors such as GW4869, which can prevent exosome secretion, can reduce the functional interactions of EPCIP with other cellular components. Similarly, agents like monensin and bafilomycin A1, which alter Golgi function and endosomal acidification, respectively, can impact the biogenesis of exosomes, thereby affecting the role of EPCIP in exosomal pathways.
Other compounds listed, such as Manumycin A and genistein, can disrupt signaling pathways by inhibiting enzyme activities like farnesyltransferase and tyrosine kinases, potentially altering the functional context in which EPCIP operates. Membrane-targeting agents such as methyl-β-cyclodextrin, filipin III, and nystatin can perturb membrane structures and composition, affecting the membrane-associated activities of EPCIP.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $199.00 $599.00 | 24 | |
Neutral sphingomyelinase inhibitor; can inhibit exosome release, potentially reducing EPCIP's exosomal interactions. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $215.00 $622.00 | 5 | |
Farnesyltransferase inhibitor; can disrupt protein prenylation, indirectly affecting EPCIP-related signaling. | ||||||
D-Mannose | 3458-28-4 | sc-211180 sc-211180A | 100 g 250 g | $101.00 $158.00 | 1 | |
Can disrupt carbohydrate-dependent protein interactions, possibly altering EPCIP's interactions in the exosomal membrane. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Ionophore that disrupts Golgi function; can impact exosome formation and possibly EPCIP packaging into exosomes. | ||||||
U 18666A | 3039-71-2 | sc-203306 sc-203306A | 10 mg 50 mg | $140.00 $500.00 | 2 | |
Cholesterol transport inhibitor; can affect cholesterol homeostasis, potentially influencing EPCIP-related pathways. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
V-ATPase inhibitor; can affect endosomal acidification, potentially impacting exosome formation and EPCIP function. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
GTPase inhibitor; can inhibit dynamin, affecting vesicle scission and potentially exosomal EPCIP release. | ||||||
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | $60.00 $108.00 | 21 | |
Blocks clathrin-mediated endocytosis; can indirectly affect exosome formation and EPCIP's role within it. | ||||||
Methyl-β-cyclodextrin | 128446-36-6 | sc-215379A sc-215379 sc-215379C sc-215379B | 100 mg 1 g 10 g 5 g | $25.00 $65.00 $170.00 $110.00 | 19 | |
Cholesterol-depleting agent; can disrupt lipid rafts, potentially affecting EPCIP's localization and function. | ||||||
Filipin III | 480-49-9 | sc-205323 sc-205323A | 500 µg 1 mg | $116.00 $145.00 | 26 | |
Cholesterol binding agent; can disturb membrane microdomains, possibly impacting EPCIP's membrane-related functions. | ||||||